MD HB755 | 2019 | Regular Session
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on February 8 2019 - 25% progression, died in chamber
Action: 2019-04-04 - Unfavorable Report by Health and Government Operations; Withdrawn
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 8 2019 - 25% progression, died in chamber
Action: 2019-04-04 - Unfavorable Report by Health and Government Operations; Withdrawn
Text: Latest bill text (Introduced) [PDF]
Summary
Requiring the Prescription Drug Monitoring Program to monitor the prescribing and dispensing of Gabapentin by all prescribers and dispensers in the State; and requiring the Maryland Department of Health to submit a report on whether Gabapentin should be added to the a controlled dangerous substances schedule to the Senate Finance Committee and the House Health and Government Operations Committee on or before December 31, 2019.
Title
Public Health - Gabapentin - Monitoring by Prescription Drug Monitoring Program and Report
Sponsors
History
| Date | Chamber | Action |
|---|---|---|
| 2019-04-04 | House | Unfavorable Report by Health and Government Operations; Withdrawn |
| 2019-02-13 | House | Hearing 2/27 at 1:00 p.m. |
| 2019-02-08 | House | First Reading Health and Government Operations |
Subjects
Controlled Dangerous Substances
Drugs
Examinations
Health
Health, Department of
Medical Treatments
Public Health
Reports
Drugs
Examinations
Health
Health, Department of
Medical Treatments
Public Health
Reports
